Tecentriq
| Tecentriq | |
|---|---|
| Term | Tecentriq |
| Short definition | Tecentriq - (pronounced) (teh-SEN-trik) drug that binds to the protein PD-L1 to help immune cells kill cancer cells better and is used to treat various types of cancer, including cancers that express PD-L1. Tecentriq is used alone or with other medicines to treat adults with certain types of hepatocellular carcinoma (a type of liver cancer), melanoma, non-small cell lung cancer or small cell lung cancer. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Tecentriq - (pronounced) (teh-SEN-trik) drug that binds to the protein PD-L1 to help immune cells kill cancer cells better and is used to treat various types of cancer, including cancers that express PD-L1. Tecentriq is used alone or with other medicines to treat adults with certain types of hepatocellular carcinoma (a type of liver cancer), melanoma, non-small cell lung cancer or small cell lung cancer. It is also used on its own to treat adults and children over 2 years of age with alveolar soft tissue sarcoma that has spread to other parts of the body or cannot be surgically removed. It is also being studied in the treatment of other types of cancer. Tecentriq can block PD-L1 and help the immune system kill cancer cells. It's a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called atezolizumab
External links
- Medical encyclopedia article on Tecentriq
- Wikipedia's article - Tecentriq
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski